MiMedx Group (NASDAQ:MDXG) Cut to "Sell" at Wall Street Zen

MiMedx Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded MiMedx Group from “hold” to “sell.” Analyst views remain mixed: MarketBeat reports six Buy ratings and one Sell rating, with an overall “Moderate Buy” consensus and an average target of $8.14.
  • MiMedx reported quarterly EPS of -$0.01 and revenue of $62.28 million, below analyst expectations of $68.56 million.
  • Shares opened at $3.06, down 1.8%, near the stock’s 12-month low of $3.03; its 50-day and 200-day moving averages were $4.11 and $4.13, respectively.
  • Five stocks to consider instead of MiMedx Group.

MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price target on shares of MiMedx Group in a report on Tuesday. Craig Hallum increased their price target on shares of MiMedx Group from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Thursday, August 27th. Mizuho set a $7.00 price objective on shares of MiMedx Group in a report on Thursday, October 29th. Weiss Ratings lowered shares of MiMedx Group from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, October 29th. Finally, Seaport Research Partners lowered shares of MiMedx Group to a "neutral" rating in a research report on Monday, August 17th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MiMedx Group has an average rating of "Moderate Buy" and an average target price of $8.14.

Read Our Latest Analysis on MiMedx Group

MiMedx Group Trading Down 1.8%

Shares of MiMedx Group stock opened at $3.06 on Friday. The business's fifty day simple moving average is $4.11 and its 200 day simple moving average is $4.13. The firm has a market capitalization of $445.82 million, a P/E ratio of -23.50 and a beta of 1.17. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.45.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $62.28 million during the quarter, compared to analysts' expectations of $68.56 million. MiMedx Group had a positive return on equity of 2.39% and a negative net margin of 6.32%. Analysts predict that MiMedx Group will post -0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. American Century Companies Inc. increased its holdings in MiMedx Group by 253.1% in the 3rd quarter. American Century Companies Inc. now owns 1,901,087 shares of the company's stock worth $8,859,000 after acquiring an additional 1,362,695 shares during the last quarter. Allworth Financial LP lifted its holdings in MiMedx Group by 59.7% during the third quarter. Allworth Financial LP now owns 10,032 shares of the company's stock valued at $47,000 after purchasing an additional 3,751 shares during the last quarter. Private Capital Management LLC lifted its holdings in MiMedx Group by 886.2% during the third quarter. Private Capital Management LLC now owns 193,206 shares of the company's stock valued at $900,000 after purchasing an additional 173,615 shares during the last quarter. Aquatic Capital Management LLC lifted its holdings in MiMedx Group by 365.6% during the third quarter. Aquatic Capital Management LLC now owns 23,923 shares of the company's stock valued at $111,000 after purchasing an additional 18,785 shares during the last quarter. Finally, Cetera Investment Advisers boosted its position in MiMedx Group by 15.5% during the third quarter. Cetera Investment Advisers now owns 56,420 shares of the company's stock worth $263,000 after purchasing an additional 7,568 shares during the period. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company's products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.

Featured Articles

Analyst Recommendations for MiMedx Group (NASDAQ:MDXG)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MiMedx Group Right Now?

Before you consider MiMedx Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.

While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines